Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth, wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fibre growth, wherein the oral or topical composition comprises ≦9, preferably ≦8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

A pourable, non-toxic lubricating composition containing lambda carrageenan as an antiviral agent, for protection from viruses, including but not limited to sexually-transmitted viruses and respiratory viruses, and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of sexually-transmitted viruses, including HPV, during sexual activity.

A tincture composition includes gel-free sea moss extract; about 80-90% by volume glycerin; about 10-18% by volume ethanol; and about 0.5-1.5% cinnamon oil. The total amount of glycerin, ethanol, and cinnamon oil is 100%. A method of producing the composition includes soaking sea moss in water; drying the sea moss; immersing the sea moss fully in glycerin; providing an extraction blend; blending the sea moss, the glycerin, and the extraction blend to form a suspension; straining the suspension to extract a tincture; and heating the tincture at 50-200 degrees Fahrenheit for 1-24 hours. The extraction blend includes, per 1 part by volume glycerin: 1/16 to 2 parts by volume ethanol and 1/100 to ¼ parts by volume of cinnamon oil. The tincture composition has an excellent shelf life and improved palatability. A binding agent may be added to prevent separation.

A tincture composition includes gel-free sea moss extract; about 80-90% by volume glycerin; about 10-18% by volume ethanol; and about 0.5-1.5% cinnamon oil. The total amount of glycerin, ethanol, and cinnamon oil is 100%. A method of producing the composition includes soaking sea moss in water; drying the sea moss; immersing the sea moss fully in glycerin; providing an extraction blend; blending the sea moss, the glycerin, and the extraction blend to form a suspension; straining the suspension to extract a tincture; and heating the tincture at 50-200 degrees Fahrenheit for 1-24 hours. The extraction blend includes, per 1 part by volume glycerin: 1/16 to 2 parts by volume ethanol and 1/100 to ¼ parts by volume of cinnamon oil. The tincture composition has an excellent shelf life and improved palatability. A binding agent may be added to prevent separation.

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in the treatment or prevention of an infection caused by microsporidia in humans or animals. It has useful properties as an antiparasitic agent in humans or animals; for the treatment or prevention of an infection caused by at least one microsporidia in humans or animals; in particular for the treatment or prevention of an infection caused in bees by the microsporidia Nosema, preferably Nosema ceranae or Nosema apis, or indeed for stimulating the immune defences of bees.

The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in the treatment or prevention of an infection caused by microsporidia in humans or animals. It has useful properties as an antiparasitic agent in humans or animals; for the treatment or prevention of an infection caused by at least one microsporidia in humans or animals; in particular for the treatment or prevention of an infection caused in bees by the microsporidia Nosema, preferably Nosema ceranae or Nosema apis, or indeed for stimulating the immune defences of bees.

The present invention provides crude extracts from the red seaweeds: Polysiphonia lanosa (PL), Polysiphonia urceloata (PU), Cystoclonium purpureum (CP) and Devaleraea ramentacia (DR), method of preparation and their use for inhibiting the growth of microbial cells, particularly bacteria causing acne, such as Propionibacterium acnes, or causing nosocomial infections such as MRSA in humans or MRSP in dogs.